Quick Verdict
ARA-290
Risk
Half-life
~3 hours
Vladonix
Risk
Half-life
—
Side-by-Side Comparison
About ARA-290
Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing
A modified erythropoietin peptide that activates tissue repair pathways without stimulating red blood cell production. Strong evidence for neuropathic pain and sarcoidosis.
Research Areas
About Vladonix
Short peptide complex penetrates cell nuclei and modulates gene expression in thymic and T-lymphocyte cells. Promotes T-cell maturation, normalizes CD4/CD8 ratios, and supports cytokine balance.
A short peptide bioregulator derived from thymus tissue, developed by the Khavinson Institute in St. Petersburg. Designed to restore thymus function and normalize immune activity in aging populations where thymic involution has reduced immune competence.
Research Areas
Find Providers
Where to source these peptides
Providers offering
ARA-290
12 listed
Browse directory →
Providers offering
Vladonix
1 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More longevity Comparisons
Browse all peptides →Educational research tools — not medical advice.